{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:46:29Z","timestamp":1791888389357,"version":"4.3.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T00:00:00Z","timestamp":1518825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T00:00:00Z","timestamp":1518825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10637-017-0544-y","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T20:28:16Z","timestamp":1518812896000},"page":"647-656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors"],"prefix":"10.1007","volume":"36","author":[{"given":"Hideki","family":"Ueno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Andre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Tajimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruyasu","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,17]]},"reference":[{"key":"544_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.devcel.2008.11.010","volume":"15","author":"J Jiang","year":"2008","unstructured":"Jiang J, Hui CC (2008) Hedgehog signaling in development and cancer. Dev Cell 15:801\u2013812","journal-title":"Dev Cell"},{"key":"544_CR2","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1021\/jm801420y","volume":"52","author":"N Mahindroo","year":"2009","unstructured":"Mahindroo N, Punchihewa C, Fujii N (2009) Hedgehog-Gli signaling pathway inhibitors as anticancer agents. J Med Chem 52:3829\u20133845","journal-title":"J Med Chem"},{"key":"544_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/cancers8020022","volume":"8","author":"TK Rimkus","year":"2016","unstructured":"Rimkus TK, Carpenter RL, Qasem S, Chan M, Lo HW (2016) Targeting the sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors. Cancers (Basel) 8:22","journal-title":"Cancers (Basel)"},{"issue":"Suppl 8","key":"544_CR4","doi-asserted-by":"publisher","first-page":"Abstract 2819","DOI":"10.1158\/1538-7445.AM2011-2819","volume":"71","author":"MH Bender","year":"2011","unstructured":"Bender MH, Hipskind PA, Capen AR, Cockman M, Credille KM, Gao H, Bastian JA, Clay JM, Lobb KL, Sall DJ, Thompson ML, Wilson T, Wishart GN, Patel BKR (2011) Identification and characterization of a novel smoothened antagonist for the treatment of cancer with deregulated hedgehog signaling. Cancer Res 71(Suppl 8):Abstract 2819","journal-title":"Cancer Res"},{"issue":"Suppl 2","key":"544_CR5","doi-asserted-by":"publisher","first-page":"Abstract B32","DOI":"10.1158\/1535-7163.TARG-15-B32","volume":"14","author":"J Bendell","year":"2015","unstructured":"Bendell J, Andre V, Ho A, Kudchadkar R, Migden M, Infante J, Tiu R, Pitou C, Tucker T, Brail L, Von Hoff D (2015) LY2940680, a hedgehog (Hh) pathway inhibitor, demonstrates antitumor activity in patients with advanced basal cell carcinoma (BCC). Mol Cancer Ther 14(Suppl 2):Abstract B32","journal-title":"Mol Cancer Ther"},{"issue":"Suppl 6","key":"544_CR6","first-page":"Abstract 594","volume":"48","author":"J Bendell","year":"2012","unstructured":"Bendell J, Weiss G, Infante J, Ramanathan R, Jones S, Korn R, Burris H, Brail L, Jones E, Von Hoff D (2012) A phase I dose-escalation, pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of LY2940680, an oral Smo inhibitor. Eur J Cancer 48(Suppl 6):Abstract 594","journal-title":"Eur J Cancer"},{"key":"544_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"544_CR8","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.1158\/1078-0432.CCR-09-0344","volume":"15","author":"PH O'Donnell","year":"2009","unstructured":"O'Donnell PH, Dolan ME (2009) Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res 15:4806\u20134814","journal-title":"Clin Cancer Res"},{"key":"544_CR9","doi-asserted-by":"crossref","unstructured":"Schaefer E, Braiteh F, Forster M, Talbot D, Chandler J, Richards D, Andre V, Estrem S, Pitou C, Tiu R, Brail L, Nikolinakos P (2016) Phase 1b\/2 trial of taladegib (LY2940680), a Hh\/Smo inhibitor, in combination with carboplatin and etoposide followed by taladegib maintenance in extensive-stage small-cell lung cancer. Eur J Cancer 69(Suppl 1):Abstract 399","DOI":"10.1016\/S0959-8049(16)32990-2"},{"key":"544_CR10","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","volume":"366","author":"A Sekulic","year":"2012","unstructured":"Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A (2012) Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366:2171\u20132179","journal-title":"N Engl J Med"},{"key":"544_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2013.09.012","volume":"70","author":"AL Chang","year":"2014","unstructured":"Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, Chen DM, Weiss GJ (2014) Expanded access study of patients with advanced basal cell carcinoma treated with the hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol 70:60\u201369","journal-title":"J Am Acad Dermatol"},{"key":"544_CR12","doi-asserted-by":"crossref","unstructured":"Casey D, Demko S, Shord S, Zhao H, Chen H, He K, Putman A, Helms WS, Keegan P, Pazdur R (2017) FDA approval summary: Sonidegib for locally advanced basal cell carcinoma. Clin Cancer Res 23:2377\u20132381","DOI":"10.1158\/1078-0432.CCR-16-2051"},{"key":"544_CR13","doi-asserted-by":"crossref","unstructured":"Schaefer E, Braiteh F, Forster M, Talbot D, Chandler J, Richards D, Andre V, Estrem S, Pitou C, Tiu R, Brail L, Nikolinakos P (2016) Phase 1b\/2 trial of taladegib (LY2940680), a Hh\/Smo inhibitor, in combination with carboplatin and etoposide followed by taladegib maintenance in extensive-stage small-cell lung cancer. Poster presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 2016 (Poster 399)","DOI":"10.1016\/S0959-8049(16)32990-2"},{"key":"544_CR14","doi-asserted-by":"publisher","first-page":"a013581","DOI":"10.1101\/cshperspect.a013581","volume":"4","author":"SX Atwood","year":"2014","unstructured":"Atwood SX, Whitson RJ, Oro AE (2014) Advanced treatment for basal cell carcinomas. Cold Spring Harb Perspect Med 4:a013581","journal-title":"Cold Spring Harb Perspect Med"},{"key":"544_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/annonc\/mdn533","volume":"20","author":"G Randi","year":"2009","unstructured":"Randi G, Malvezzi M, Levi F, Ferlay J, Negri E, Franceschi S, La Vecchia C (2009) Epidemiology of biliary tract cancers: an update. Ann Oncol 20:146\u2013159","journal-title":"Ann Oncol"},{"key":"544_CR16","first-page":"12","volume":"5","author":"YJ Kim","year":"2012","unstructured":"Kim YJ, Park SB, Park JY, Park SW, Chung JB, Song SY, Bang S (2012) The sonic hedgehog pathway as a treatment target for extrahepatic biliary tract cancer. Mol Med Rep 5:12\u201316","journal-title":"Mol Med Rep"},{"key":"544_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11010-014-2161-9","volume":"396","author":"T Kiesslich","year":"2014","unstructured":"Kiesslich T, Mayr C, Wachter J, Bach D, Fuereder J, Wagner A, Alinger B, Pichler M, Di Fazio P, Ocker M, Berr F, Neureiter D (2014) Activated hedgehog pathway is a potential target for pharmacological intervention in biliary tract cancer. Mol Cell Biochem 396:257\u2013268","journal-title":"Mol Cell Biochem"},{"key":"544_CR18","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/jhbp.107","volume":"21","author":"D Riedlinger","year":"2014","unstructured":"Riedlinger D, Bahra M, Boas-Knoop S, Lippert S, Bradtmoller M, Guse K, Seehofer D, Bova R, Sauer IM, Neuhaus P, Koch A, Kamphues C (2014) Hedgehog pathway as a potential treatment target in human cholangiocarcinoma. J Hepatobiliary Pancreat Sci 21:607\u2013615","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"544_CR19","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/bjc.2014.625","volume":"112","author":"M Zuo","year":"2015","unstructured":"Zuo M, Rashid A, Churi C, Vauthey JN, Chang P, Li Y, Hung MC, Li D, Javle M (2015) Novel therapeutic strategy targeting the hedgehog signalling and mTOR pathways in biliary tract cancer. Br J Cancer 112:1042\u20131051","journal-title":"Br J Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-017-0544-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0544-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0544-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T13:22:10Z","timestamp":1678540930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-017-0544-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,17]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["544"],"URL":"https:\/\/doi.org\/10.1007\/s10637-017-0544-y","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,17]]},"assertion":[{"value":"3 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KI and MT are employees of Eli Lilly Japan K.K. and VA is an employee of Eli Lilly and Company. VA and MT own stock in Eli Lilly and Company. HU has received research funding from Eli Lilly, Baxalta, NanoCarrier, and Taiho Pharmaceutical and has served on a Speaker\u2019s Bureau for Taiho Pharmaceutical. HM has received honoraria from Eli Lilly Japan K.K., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Japan, Chugai Pharmaceutical Co., Ltd., Clovis Oncology, Nippon Kayaku, Novartis, Ono Pharmaceutical Co., Ltd., Pfizer, Taiho Pharmaceutical, and Teijin Pharma Limited.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}